
    
      This study is aimed at providing further clinical evidence to support or refute the current
      understanding of biological sensitivity of prostate cancer to fractionated radiotherapy.
      Determining the morbidity and cancer control provided by a 4-week course of treatment will
      greatly influence future radiotherapy services for patients with localized prostate cancer.
    
  